Aerovate Therapeutics Inc expected to post a loss of 76 cents a share - Earnings Preview

Jade Biosciences

10/05/2024 13:05

* Aerovate Therapeutics Inc  AVTE.OQ   AVTE.O  is expected
to show
no change in quarterly revenue when it reports  results on May
13 (estimated) for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Aerovate Therapeutics
Inc is
for a loss of 76 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 7 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 0.2%
in the last three months. ​
    * Wall Street's median 12-month price target for Aerovate
Therapeutics Inc is $45.50​, above​ its last closing price
of $21.56. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -0.71       -0.71      -0.74     Missed  -4.6
 Jan. 1 0001   -0.70       -0.69      -0.71     Missed  -2.7
 Jun. 30 2023  -0.70       -0.70      -0.76     Missed  -9.2​
 Jan. 1 0001   -0.61       -0.60      -0.67     Missed  -11.7
 ​​Dec.        -0.71       -0.62      -0.61     Beat    1.3
 31 2022                                                
 Jan. 1 0001   -0.50       -0.50      -0.56     Missed  -12.4​
 Jun. 30 2022  -0.46       -0.45      -0.49     Missed  -7.8
 Mar. 31 2022  -0.34       -0.28      -0.45     Missed  -62.2
 This summary was machine generated May 10 at 12:05 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)